Diabetic Retinopathy News and Research RSS Feed - Diabetic Retinopathy News and Research

In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME. [More]
Loyola ophthalmologist recommends specific foods and supplements for healthy vision

Loyola ophthalmologist recommends specific foods and supplements for healthy vision

You may remember your mother telling you to eat your carrots; they are good for your eyes. Well, she was right. "Carrots are actually just one of the many foods, and supplements that contribute to good eye health," says James McDonnell, MD, pediatric ophthalmologist, Loyola University Health System. "In some cases, eyesight can actually be improved depending on what you eat." [More]
UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

UTSA professor named Gold Fellow of the Association for Research in Vision and Ophthamology

Andrew Tsin, professor of biology in the UTSA College of Sciences, has been named a Gold Fellow of the Association for Research in Vision and Ophthamology for his dedication and exemplary contributions in the field. Tsin will receive the honor at the 2015 ARVO Annual Meeting, May 3-7 in Denver. [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured [More]
Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs -- Eylea, Avastin and Lucentis -- used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe. [More]
UW ophthalmology researchers help show effectiveness of three drugs for treating DME

UW ophthalmology researchers help show effectiveness of three drugs for treating DME

An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss. [More]
Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Clinical study comparing effectiveness of three standard treatments for DME published in NEJM

Regeneron Pharmaceuticals, Inc. today announced that results from the National Institutes of Health-sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T) were published in the New England Journal of Medicine and a corresponding slide set was posted online at DRCR.net. [More]
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. [More]
Choroidal thickness reduced in diabetic macular oedema patients

Choroidal thickness reduced in diabetic macular oedema patients

Patients with diabetic macular oedema have smaller choroidal thickness measurements in affected and unaffected eyes compared with healthy individuals, spectral-domain optical coherence tomography imaging results reveal. [More]
Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests. [More]

Retinal function affected early in Type 1, 2 diabetes

Visual dysfunction manifests early in Type 1 and Type 2 diabetes, research shows, with functional impairment detected in patients with nonproliferative diabetic retinopathy lacking clinical signs and symptoms of diabetic macular oedema. [More]
OIB Program helps older Californians with blindness to live and work independently

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma. [More]
Study: Lower-income students in China have better vision compared to middle-class counterparts

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu. [More]
Reversing effects of early stage age-related macular degeneration may be possible

Reversing effects of early stage age-related macular degeneration may be possible

A new technique reported in the February 2015 issue of The FASEB Journal suggests that during early stages, it might be possible to reverse age-related macular degeneration, a leading cause of blindness that is currently irreversible. The treatment involving a nanosecond laser may also have further implications for other eye diseases such as diabetic macular oedema, diabetic retinopathy and retinopathy of prematurity. [More]
National Centre for Healthcare Photonics to be located in North East of England

National Centre for Healthcare Photonics to be located in North East of England

One of the most interesting and fastest developing areas in healthcare is the use of light to diagnose and treat medical conditions and illnesses, collectively known as Healthcare Photonics. It includes a range of new phototherapies as well as bio-medical imaging and in vitro diagnostics. The area offers huge potential for the UK and the global healthcare sector. Applications are wide ranging from wound, skin and cancer care to niche applications in neurology and ophthalmology. [More]
Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, and LKC Technologies, Inc., the worldwide leader in visual electrophysiology and inventor of the RETeval DR diabetic retinopathy assessment device announced an exclusive distribution agreement. [More]
Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Peroxisome proliferator–activated receptor α exerts protective effects on retinal pericytes, shows research that explains why fenofibrate is protective against diabetic retinopathy. [More]
Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). [More]
Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham. [More]
Advertisement
Advertisement